Type VI-E and type VI-F CRISPR-Cas system and uses thereof
US11225659B2 · kind B2 · utility
0Cited by
1References
30Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | May 1, 2020 |
| Grant date | Jan 18, 2022 |
| Priority date | — |
| Expiry date | Jun 30, 2040 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2800/80
- WIPO fieldBiotechnology
- WIPO sectorChemistry
Abstract
The invention provides novel CRISPR/Cas compositions and uses thereof for targeting nucleic acids. In particular, the invention provides non-naturally occurring or engineered RNA-targeting systems comprising a novel RNA-targeting Cas13e or Cas13f effector protein, and at least one targeting nucleic acid component such as a guide RNA (gRNA) or crRNA. The novel Cas effector proteins are among the smallest of the known Cas effector proteins, at about 800 amino acids in size, and are thus uniquely suitable for delivery using vectors of small capacity, such as an AAV vector.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.